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The term 'postmarketing surveillance' refers to analyses for the purpose of detecting adverse drug reactions in data accumulated after a medicinal product has been authorized by a regulatory agency [1] [2] [3] . The current regulatory process has systematic provisions for obtaining important data needed to ensure the safety of novel drugs almost exclusively during premarketing testing [4] . However, premarketing trials frequently do not have sufficient power to reliably detect important adverse drug reactions [5] . This is because trials are usually powered for the intended therapeutic effect, and are therefore underpowered for side effects that are rarer than the therapeutic effects. In addition, registration trials are often performed in a relatively healthy subset of patients with the condition of interest, and exclude users of comedications, thereby reducing the likelihood of detecting drug-drug interactions [5] . Therefore, postmarketing surveillance has been introduced to fill this gap by evaluating the safety of medicinal products and to determine unexpected effects occurring after marketing authorization. In the last few years, there has been an increasing worldwide emphasis on the development of improved strategies to evaluate the safety of new drugs in the postmarketing phase [6, 7] in various fields, including hemophilia.
As a large number of novel products for hemophilia treatment have recently been licensed or will be licensed soon, such as modified clotting factor concentrates with extended half-lives (PEGylated, Fc-fusion or albuminfusion products) and alternative hemostasis-enhancing drugs (anti-TFPI, ALN-AT3, or ACE910), we need to have a systematic approach to postmarketing surveillance, in order to monitor their long-term safety.
Therapeutic effects of drugs need to be studied in randomized trials, as physicians will invariably tie prescription of a specific drug to the risk profile of the patient, according to factors that are usually too subtle to measure and control for. This confounding by indication may distort the results. For adverse events, few risk factors are usually known, so confounding is less of a problem, but it should still be carefully considered. As it is not usually feasible to assess side effects in randomized trials, observational studies are more suitable for assessing safety. However, it should be kept in mind that confounding and incomparability of groups remain the main issues in observational study designs.
Observational studies can either be cohort or case-control studies. The guidelines for cohort studies (see reporting guidelines such as STROBE [8] ) also apply to the study of adverse effects: an unbiased inception cohort is formed and followed over time. Ideally, all eligible individuals in a well-defined region and time window are included from the time of becoming eligible, and are all followed in a similar way. Deviation from this ideal should be considered for its potential to create biases, the most important of which is selective inclusion of patients. This results in many registers resembling case series rather than an appropriate baseline sample of a cohort study. The minimum requirement is that participating centers include consecutive patients without selection.
An efficient alternative to cohort studies is to perform case-control studies, which are generally seen as the optimal design with which to assess adverse drug reactions, as they maximize power and efficiency. In this design, new cases of patients with the complication of interest are included and compared with patients without it. A requisite here is an unbiased database of patients with the complication of interest, and an appropriate control group. Although this design maximizes power, drawbacks are that only one type of adverse event can be studied, and that only relative rates can be computed, and not absolute risks.
When true registers are built as inception cohorts, the two designs can both be employed within the information base along with powerful mixed forms such as nested case-control studies.
Within the framework of the ISTH Scientific and Standardization Subcommittee (SSC) on Factor VIII, Factor IX and Rare Coagulation Disorders, a working group was appointed to optimize a minimum standardized set of data necessary to provide information on the safety of new drugs after product registration.
The ISTH SSC working group consists of physicians, representatives of national and international registries, epidemiologists, and representatives of regulatory agencies and patient organizations (see Acknowledgements).
The members of this working group collaborated to draft a minimal standardized dataset, starting from a critical analysis of the information reported in all available national and international databases/registers (American Thrombosis and Hemostasis Network; Canadian Hemophilia Surveillance System; European Haemophilia Safety Surveillance; FranceCoag database; PedNet Haemophilia Registry; and United Kingdom Haemophilia Centres Doctors' Organization database). A preliminary data collection scheme was submitted first to the regulatory agencies, then to patient associations (World Federation of Hemophilia National Hemophilia Foundation, and European Haemophilia consortium) and then to pharmaceutical companies for collection of their suggestions and comments. Then, a core set of information to be collected was consolidated as shown in Data S1.
Collection dataset
The ISTH SSC working group has developed an essential and user-friendly data format for pharmacovigilance (Data S1). All hemophilic patients in a participating center treated for the first time with a new hemostatic product, regardless of severity and age, should be registered, including previously untreated patients (PUPs) and previously treated patients (PTPs), in order to monitor accurately the onset of any drug-related adverse events.
The electronic data collection form (Data S1) requires the following information, divided into baseline data at entry and regularly completed follow-up data: ABaseline data 4 Treatment data: details on products and regimens to be provided only for PUPs and for cases undergoing concentrate switches. 5 Adverse event notifications: all adverse events or the absence thereof should be assessed for a long period of time (at least for 3-5 years, and preferably for the entire life of a patient), including the occurrence of inhibitors, allergic/hypersensitivity reactions, death, malignancy, thromboembolic events (arterial, venous, and microangiopathic), and infections or any other unexpected side effects. Considering that, in preclinical studies, vacuolation in various tissues was observed at high doses after exposure to PEGconjugated drugs [9] [10] [11] , the introduction of new molecules will need new monitoring methods, and, as a minimum, renal and hepatic function should be monitored by annual sampling of peripheral blood (e.g. creatinine, urea, serum transaminase, alkaline phosphatase, c-glutamyl transferase, pseudocholinesterase, albumin, and bilirubin) and urine analysis (e.g. proteinuria and microalbuminuria). Any other type of unusual or unexpected adverse event (e.g. neurologic disorders or behavioral deficits, liver, kidney, and skin) needs to be recorded for any modified products. 6 Inhibitor monitoring: PTPs starting to use a new product should be followed for at least 100 exposure days (EDs), and assessed at 1, 10-15, 50-75 and 100 EDs and then annually, with registration of treatment-specific information. It will be particularly important to observe PTPs with a past history of inhibitors. The data to be collected and reported for inhibitors developing in PTPs have been described in another statement of this ISTH SSC [12] .
PUPs should be followed for at least 75 EDs, and inhibitor testing should be performed at 1, 5, 10, 20, 30, 50 and 75 EDs and then annually. The assessment of inhibitor development is based on the European Medicines Agency guideline on the clinical investigation of new FVIII and FIX products [13, 14] . A different version was developed for PTPs by the SSC of the ISTH considering the 'biphasic' nature of the inhibitor incidence after FVIII exposure: an early exposure (15 EDs, interquartile range 10-20 EDs) high peak 'epidemic' rate of up to 30% in PUPs is followed by a lifelong low 'endemic' incidence of 0.1-0.6% per patient-year [15] .
7 Levels of antibodies against the drug (PEG, Fc, etc.)
should be reported (when available and tested), including when there is a reduced half-life of the drug, even if there are no standardized assays currently available.
Data storage and analysis
The ISTH SSC working group advises that:
1 this system of data collection should be available universally in all hemophilia treatment centers, so that every patient treated for the first time with a new hemostatic agent is registered, and all adverse effects, including inhibitor development, are recorded over time; 2 all patients, both PUPs and PTPs, should be included; 3 the registration of each patient should be recorded at a national level with a unique identifier, in order to prevent duplication; 4 the unique identifier should also be implemented in international databases, in order to have a harmonized data collection system; 5 data subsets should be shared and analyzed at an international level at regular intervals by an independent body.
Conclusion
The ISTH SSC working group has formulated a consensus essential data collection tool in order to evaluate any potential side effect related to a new hemostatic product in a standardized way to allow cohort and case-control analyses. This data collection system has the advantages of being uniform and standardized, and collects information over extended time periods. It allows pooling of datasets from hemophilia treatment centers around the world in order to detect low-frequency adverse effects (not identified in premarketing clinical trials and not detectable in a single cohort) and eventually to link the information to other international databases. This instrument allows also to detect new unlabeled adverse events and unknown longterm safety issues of novel products in the entire population or specific subgroups of interest [16] .
This collection system is a common instrument for sharing information on the safety of products internationally, and implementing and exchanging knowledge on novel drugs to ensure better surveillance for the patients.
This standardized method of data collection will also allow regulators to have access to real-life data and identify any unexpected increase in immunogenicity or any unexpected or unknown side effect of a new licensed product.
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